Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANAVEX2-73 in early Alzheimer's disease
2019-003302-27Phase 2Unknown
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Nov 2019
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing ANAVEX2-73 with Placebo (2 arms). Primary endpoint: Effects of ANAVEX2-73 on cognition and functioning. Status: unknown.
02
Drugs
blarcamesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2019-003302-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003302-27.